Haiping Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Haiping Wang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Liang Xu
Shandong Provincial Hospital Affiliated to Shandong First Medical University Department of Nephrology Jinan
8 shared publicationsJie Gao
Shandong Provincial Hospital Affiliated to Shandong First Medical University Department of Nephrology Jinan
7 shared publicationsYao Zhang
Shandong Provincial Hospital Affiliated to Shandong First Medical University Department of Nephrology Jinan
6 shared publicationsJing Lu
Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
4 shared publicationsJing Sun
Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
4 shared publications- Jing Sun
Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
4 shared publications
Latest Publications
- Open Access
- 25 September 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (9)
Multiple Imaging Modalities in the Diagnosis of Infective Endocarditis
Infective endocarditis (IE) is an inflammatory disease caused by the infection of the endocardium or heart valves by pathogenic microorganisms. It is characterized by diagnostic challenges, difficult treatment, and high mortality. Multimodal imaging techniques, including echocardiography, computed tomography (CT), magnetic resonance imaging (MRI), and nuclear medicine imaging, play a crucial role in the diagnosis of IE. Echocardiography is the first-line imaging modality for suspected IE. Cardiac CT, with its excellent spatial resolution and three-dimensional (3D) reconstruction capabilities, is helpful in detecting paravalvular abscesses, fistulas, and pseudoaneurysms. MRI has advantages in identifying neurological complications and assessing myocardial involvement. Nuclear imaging demonstrates high specificity in detecting prosthetic valve IE and device-related infections. These imaging techniques are important in detecting perivalvular complications, evaluating local and distant spread of infection, and guiding therapeutic interventions, thereby enhancing the diagnostic and therapeutic management of IE.
- 25 September 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (9)
Open AccessMultiple Imaging Modalities in the Diagnosis of Infective Endocarditis
Infective endocarditis (IE) is an inflammatory disease caused by the infection of the endocardium or heart valves by pathogenic microorganisms. It is characterized by diagnostic challenges, difficult treatment, and high mortality. Multimodal imaging techniques, including echocardiography, computed tomography (CT), magnetic resonance imaging (MRI), and nuclear medicine imaging, play a crucial role in the diagnosis of IE. Echocardiography is the first-line imaging modality for suspected IE. Cardiac CT, with its excellent spatial resolution and three-dimensional (3D) reconstruction capabilities, is helpful in detecting paravalvular abscesses, fistulas, and pseudoaneurysms. MRI has advantages in identifying neurological complications and assessing myocardial involvement. Nuclear imaging demonstrates high specificity in detecting prosthetic valve IE and device-related infections. These imaging techniques are important in detecting perivalvular complications, evaluating local and distant spread of infection, and guiding therapeutic interventions, thereby enhancing the diagnostic and therapeutic management of IE.
- Top Cited PapersOpen Access
- 1 May 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (5) , sfaf026
Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy
Background: Clinical experience with obinutuzumab in patients with rituximab-refractory phospholipase A2 receptor (PLA2R)-associated membranous nephropathy remains limited. This study aimed to evaluate the efficacy and safety of obinutuzumab in treating patients with rituximab-refractory PLA2R-associated membranous nephropathy. Methods: A single-center retrospective study was conducted on 20 patients with rituximab-refractory PLA2R-associated membranous nephropathy who received two doses of 1 g obinutuzumab, administered 2 weeks apart. At 6 months, patients with urinary protein levels exceeding 3.5 g/d received an additional dose of 1–2 g obinutuzumab. The primary clinical outcome was a composite measure of complete or partial remission during follow-up. Continuous secondary outcomes included 24-hour urinary protein, serum albumin, serum creatinine, serum anti-PLA2R levels, and CD19 B-cell counts at the time of obinutuzumab infusion, at 3 months, and at the last visit. Results: A total of 20 patients with clinical manifestations of nephrotic syndrome were included in this study, with a median follow-up period of 9 months. The mean age of the patients was 46.25 ± 13.05 years. At a median follow-up of 4.50 months (3.00–8.25 months) after obinutuzumab therapy, remission was achieved in 16 patients. Two patients (10%) achieved complete remission, while 14 (70%) attained partial remission. At baseline, 16 out of 20 patients tested positive for serum anti-PLA2R antibodies, and immunological remission was observed in 11 of these 16 patients during follow-up. All patients experienced B-lymphocyte depletion within 1 month after receiving obinutuzumab infusion and maintained this depletion at 3 months. B-lymphocyte reconstitution was noted in 4 out of 20 patients (20%) at 6 months. No patients experienced fatal adverse events. Conclusion: Obinutuzumab mainly induces short-term partial remissions in patients with rituximab-refractory primary membranous nephropathy, which may be related to the short follow-up period. However, this study demonstrates that obinutuzumab is an effective and safe treatment for rituximab-refractory PLA2R-associated membranous nephropathy.
- 1 May 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (5) , sfaf026
Top Cited PapersOpen AccessObinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy
Background: Clinical experience with obinutuzumab in patients with rituximab-refractory phospholipase A2 receptor (PLA2R)-associated membranous nephropathy remains limited. This study aimed to evaluate the efficacy and safety of obinutuzumab in treating patients with rituximab-refractory PLA2R-associated membranous nephropathy. Methods: A single-center retrospective study was conducted on 20 patients with rituximab-refractory PLA2R-associated membranous nephropathy who received two doses of 1 g obinutuzumab, administered 2 weeks apart. At 6 months, patients with urinary protein levels exceeding 3.5 g/d received an additional dose of 1–2 g obinutuzumab. The primary clinical outcome was a composite measure of complete or partial remission during follow-up. Continuous secondary outcomes included 24-hour urinary protein, serum albumin, serum creatinine, serum anti-PLA2R levels, and CD19 B-cell counts at the time of obinutuzumab infusion, at 3 months, and at the last visit. Results: A total of 20 patients with clinical manifestations of nephrotic syndrome were included in this study, with a median follow-up period of 9 months. The mean age of the patients was 46.25 ± 13.05 years. At a median follow-up of 4.50 months (3.00–8.25 months) after obinutuzumab therapy, remission was achieved in 16 patients. Two patients (10%) achieved complete remission, while 14 (70%) attained partial remission. At baseline, 16 out of 20 patients tested positive for serum anti-PLA2R antibodies, and immunological remission was observed in 11 of these 16 patients during follow-up. All patients experienced B-lymphocyte depletion within 1 month after receiving obinutuzumab infusion and maintained this depletion at 3 months. B-lymphocyte reconstitution was noted in 4 out of 20 patients (20%) at 6 months. No patients experienced fatal adverse events. Conclusion: Obinutuzumab mainly induces short-term partial remissions in patients with rituximab-refractory primary membranous nephropathy, which may be related to the short follow-up period. However, this study demonstrates that obinutuzumab is an effective and safe treatment for rituximab-refractory PLA2R-associated membranous nephropathy.
- Open Access
- 16 December 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1532774
Corrigendum: Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
• please read through all the templates before choosing• pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below.• please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary• submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates.There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.
- 16 December 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1532774
Open AccessCorrigendum: Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
• please read through all the templates before choosing• pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below.• please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary• submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates.There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.
- Open Access
- 12 December 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1532797
Corrigendum: Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling
• please read through all the templates before choosing• pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below.• please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary• submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates.There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.
- 12 December 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1532797
Open AccessCorrigendum: Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling
• please read through all the templates before choosing• pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below.• please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary• submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates.There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.
- Open Access
- 26 January 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1347880
Case report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia
Rituximab (RTX) is a monoclonal antibody commonly used to treat PLA2R-associated membranous nephropathy (MN). This report presents a case of refractory MN in a patient who experienced severe hypokalemia, a rare but clinically significant condition, after the 5th RTX infusion. Clinicians should be aware of the potential for hypokalemia and its management during or after RTX infusion. After the onset of hypokalemia, the patient received treatment with obinutuzumab and achieved partial remission of renal disease without experiencing further hypokalemia. Obinutuzumab may be a viable alternative therapy for refractory membranous nephropathy that develops side effects after rituximab therapy or is refractory to it, but further studies are necessary to determine its efficacy and safety.
- 26 January 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1347880
Open AccessCase report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia
Rituximab (RTX) is a monoclonal antibody commonly used to treat PLA2R-associated membranous nephropathy (MN). This report presents a case of refractory MN in a patient who experienced severe hypokalemia, a rare but clinically significant condition, after the 5th RTX infusion. Clinicians should be aware of the potential for hypokalemia and its management during or after RTX infusion. After the onset of hypokalemia, the patient received treatment with obinutuzumab and achieved partial remission of renal disease without experiencing further hypokalemia. Obinutuzumab may be a viable alternative therapy for refractory membranous nephropathy that develops side effects after rituximab therapy or is refractory to it, but further studies are necessary to determine its efficacy and safety.
- Open Access
- 28 July 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1106339
Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
Apolipoprotein A-I (apoA-I), 90% of which is present in high-density lipoprotein (HDL), is the main constituent of HDL, has anti-inflammatory and anti-oxidant properties, and has received extensive attention in anti-atherosclerosis. Yet little is known about apoA-I ’s role in peritoneal dialysis. In this study, by analyzing PD patients (n = 81), we found that decreased apoA/HDL-C ratio is significantly associated with rapid decline in peritoneal function. Further studies were performed in animal experiments to determine the ascendancy of apolipoprotein A-I mimetic peptide (D-4F) on peritoneum, we found that D-4F administration reduced peritoneal fibrosis and peritoneal endothelial mesenchymal transformation (EMT) induced by high glucose peritoneal dialysate, such as N-cadherin, Fibronectin, Vimentin, and α-smooth muscle actin (α-SMA) expression decreased. In mechanism, D-4F can significantly inhibit Smad2/3 phosphorylation, which is the major pathway leading to fibrosis. Furthermore, D-4F treatment inhibited NADPH oxidase and thiobarbituric acid reactive substances (TBARS) expression, increased the activity of certain enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). Finally, treatment with D-4F inhibits the expression of interleukins-6(IL-6), Interleukin-1β(IL-1β), and tumor necrosis factor-α(TNF-α). Taken together, based on the above research evidence, apoA-I and its peptide mimic may regulate the oxidative stress, TGF- β1/Smads signaling pathway and inflammatory response to reduce peritoneal fibrosis due to peritoneal dialysis.
- 28 July 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1106339
Open AccessApolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
Apolipoprotein A-I (apoA-I), 90% of which is present in high-density lipoprotein (HDL), is the main constituent of HDL, has anti-inflammatory and anti-oxidant properties, and has received extensive attention in anti-atherosclerosis. Yet little is known about apoA-I ’s role in peritoneal dialysis. In this study, by analyzing PD patients (n = 81), we found that decreased apoA/HDL-C ratio is significantly associated with rapid decline in peritoneal function. Further studies were performed in animal experiments to determine the ascendancy of apolipoprotein A-I mimetic peptide (D-4F) on peritoneum, we found that D-4F administration reduced peritoneal fibrosis and peritoneal endothelial mesenchymal transformation (EMT) induced by high glucose peritoneal dialysate, such as N-cadherin, Fibronectin, Vimentin, and α-smooth muscle actin (α-SMA) expression decreased. In mechanism, D-4F can significantly inhibit Smad2/3 phosphorylation, which is the major pathway leading to fibrosis. Furthermore, D-4F treatment inhibited NADPH oxidase and thiobarbituric acid reactive substances (TBARS) expression, increased the activity of certain enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). Finally, treatment with D-4F inhibits the expression of interleukins-6(IL-6), Interleukin-1β(IL-1β), and tumor necrosis factor-α(TNF-α). Taken together, based on the above research evidence, apoA-I and its peptide mimic may regulate the oxidative stress, TGF- β1/Smads signaling pathway and inflammatory response to reduce peritoneal fibrosis due to peritoneal dialysis.
- Open Access
- 2 February 2023
- Published by Springer Nature in BioMedical Engineering OnLine
- Vol. 22 (1) , 1-24
Computer-aided diagnosis of primary membranous nephropathy using expert system
Background: The diagnosis of primary membranous nephropathy (PMN) often depends on invasive renal biopsy, and the diagnosis based on clinical manifestations and target antigens may not be completely reliable as it could be affected by uncertain factors. Moreover, different experts could even have different diagnosis results due to their different experiences, which could further impact the reliability of the diagnosis. Therefore, how to properly integrate the knowledge of different experts to provide more reliable and comprehensive PMN diagnosis has become an urgent issue. Methods: This paper develops a belief rule-based system for PMN diagnosis. The belief rule base is constructed based on the knowledge of the experts, with 9 biochemical indicators selected as the input variables. The belief rule-based system is developed of three layers: (1) input layer; (2) belief rule base layer; and (3) output layer, where 9 biochemical indicators are selected as the input variables and the diagnosis result is provided as the conclusion. The belief rule base layer is constructed based on the knowledge of the experts. The final validation was held with gold pattern clinical cases, i.e., with known and clinically confirmed diagnoses. Results: 134 patients are used in this study, and the proposed method is defined by its sensitivity, specificity, accuracy and area under curve (AUC), which are 98.0%, 96.9%, 97.8% and 0.93, respectively. The results of this study present a novel and effective way for PMN diagnosis without the requirement of renal biopsy. Conclusions: Through analysis of the diagnosis results and comparisons with other methods, it can be concluded that the developed system could help diagnose PMN based on biochemical indicators with relatively high accuracy. Graphical
- 2 February 2023
- Published by Springer Nature in BioMedical Engineering OnLine
- Vol. 22 (1) , 1-24
Open AccessComputer-aided diagnosis of primary membranous nephropathy using expert system
Background: The diagnosis of primary membranous nephropathy (PMN) often depends on invasive renal biopsy, and the diagnosis based on clinical manifestations and target antigens may not be completely reliable as it could be affected by uncertain factors. Moreover, different experts could even have different diagnosis results due to their different experiences, which could further impact the reliability of the diagnosis. Therefore, how to properly integrate the knowledge of different experts to provide more reliable and comprehensive PMN diagnosis has become an urgent issue. Methods: This paper develops a belief rule-based system for PMN diagnosis. The belief rule base is constructed based on the knowledge of the experts, with 9 biochemical indicators selected as the input variables. The belief rule-based system is developed of three layers: (1) input layer; (2) belief rule base layer; and (3) output layer, where 9 biochemical indicators are selected as the input variables and the diagnosis result is provided as the conclusion. The belief rule base layer is constructed based on the knowledge of the experts. The final validation was held with gold pattern clinical cases, i.e., with known and clinically confirmed diagnoses. Results: 134 patients are used in this study, and the proposed method is defined by its sensitivity, specificity, accuracy and area under curve (AUC), which are 98.0%, 96.9%, 97.8% and 0.93, respectively. The results of this study present a novel and effective way for PMN diagnosis without the requirement of renal biopsy. Conclusions: Through analysis of the diagnosis results and comparisons with other methods, it can be concluded that the developed system could help diagnose PMN based on biochemical indicators with relatively high accuracy. Graphical
- Open Access
- 23 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 973182
Endoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling
Background: Peritoneal fibrosis (PF) is an intractable complication in patients on long-term peritoneal dialysis (PD). Transforming growth factor-β (TGF-β) is a key pro-fibrogenic factor involved in PD-associated PF, and endoglin, as a coreceptor for TGF-β, plays a role in balancing the TGF-β signaling pathway. Here, we investigated whether endoglin could be a potential therapeutic target for PF.Methods:In vivo, we established PF model in SD rats by daily intraperitoneal injection of peritoneal dialysis fluids (PDF) containing 4.25% glucose for 6 weeks and downregulated endoglin expression by tail vein injection of AAV9-ENG on day 14 to assess the effect of endoglin on peritoneal morphology and markers related to fibrosis, angiogenesis, and epithelial-mesenchymal transition (EMT). In vitro, we treated human peritoneal mesothelial cells (HPMCs) transfected with ENG siRNA in high glucose medium to explore the potential mechanism of endoglin in PF.Results: Compared to control group, continuous exposure to biologically incompatible PDF induced exacerbated PF, accompanied by a significant increase in endoglin expression. Conversely, knockdown of endoglin ameliorated peritoneal injury characterized by increased peritoneal thickening and collagen deposition, angiogenesis, as well as EMT. Consistently, HPMCs cultured in high glucose medium underwent the EMT process and exhibited over-expression of fibronectin, collagen type I, vascular endothelial growth factor (VEGF), whereas these aforementioned alterations were alleviated after ENG siRNA transfection. In addition, we also found that ENG siRNA inhibited TGF-β-induced phosphorylation of Smad2/3 and Smad1/5/9 in HPMCs treated with high glucose (HG).Conclusion: Our findings confirmed for the first time that endoglin exacerbated PF by regulating the activation of TGF-β/ALK/Smads signaling, which will provide a novel potential therapeutic target in PF.
- 23 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 973182
Open AccessEndoglin aggravates peritoneal fibrosis by regulating the activation of TGF-β/ALK/Smads signaling
Background: Peritoneal fibrosis (PF) is an intractable complication in patients on long-term peritoneal dialysis (PD). Transforming growth factor-β (TGF-β) is a key pro-fibrogenic factor involved in PD-associated PF, and endoglin, as a coreceptor for TGF-β, plays a role in balancing the TGF-β signaling pathway. Here, we investigated whether endoglin could be a potential therapeutic target for PF.Methods:In vivo, we established PF model in SD rats by daily intraperitoneal injection of peritoneal dialysis fluids (PDF) containing 4.25% glucose for 6 weeks and downregulated endoglin expression by tail vein injection of AAV9-ENG on day 14 to assess the effect of endoglin on peritoneal morphology and markers related to fibrosis, angiogenesis, and epithelial-mesenchymal transition (EMT). In vitro, we treated human peritoneal mesothelial cells (HPMCs) transfected with ENG siRNA in high glucose medium to explore the potential mechanism of endoglin in PF.Results: Compared to control group, continuous exposure to biologically incompatible PDF induced exacerbated PF, accompanied by a significant increase in endoglin expression. Conversely, knockdown of endoglin ameliorated peritoneal injury characterized by increased peritoneal thickening and collagen deposition, angiogenesis, as well as EMT. Consistently, HPMCs cultured in high glucose medium underwent the EMT process and exhibited over-expression of fibronectin, collagen type I, vascular endothelial growth factor (VEGF), whereas these aforementioned alterations were alleviated after ENG siRNA transfection. In addition, we also found that ENG siRNA inhibited TGF-β-induced phosphorylation of Smad2/3 and Smad1/5/9 in HPMCs treated with high glucose (HG).Conclusion: Our findings confirmed for the first time that endoglin exacerbated PF by regulating the activation of TGF-β/ALK/Smads signaling, which will provide a novel potential therapeutic target in PF.
- Open Access
- 1 February 2020
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 318 (2) , F457-F467
Nitro-oleic acid inhibits the high glucose-induced epithelial-mesenchymal transition in peritoneal mesothelial cells and attenuates peritoneal fibrosis
As an electrophilic nitroalkene fatty acid, nitro-oleic acid (OA-NO2) exerts multiple biological effects that contribute to anti-inflammation, anti-oxidative stress and anti-apoptosis. However, little is known about the role of OA-NO2 in peritoneal fibrosis. Thus, in this study, we examined the effects of OA-NO2 on the high glucose-induced epithelial-mesenchymal transition (EMT) in human peritoneal mesothelial cells (HPMCs) and evaluated the morphological and immunohistochemical changes in a rat model of peritoneal dialysis (PD)-related peritoneal fibrosis. In an in vitro study, we found that HG reduced the expression level of E-cadherin and increased snail, N-cadherin and α-SMA expression levels in the HPMCs. The abovementioned changes were attenuated by pre-treatment with OA-NO2. Additionally, OA-NO2 also inhibited the HG-induced activation of the TGF-β1/Smads signalling pathway and the NF-κB signalling pathways. Meanwhile, OA-NO2 could inhibited the HG-induced phosphorylation of Erk and JNK. The results from the in vivo study showed that OA-NO2 notably relieved peritoneal fibrosis by decreasing the thickness of the peritoneum; it also inhibited the expression of TGF-β1, α-SMA, N-cadherin and vimentin and enhanced the expression of E-cadherin in the peritoneum. Collectively, these results suggest that OA-NO2 inhibits HG-induced EMT in HPMCs and attenuates peritoneal dialysis-related peritoneal fibrosis.
- 1 February 2020
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 318 (2) , F457-F467
Open AccessNitro-oleic acid inhibits the high glucose-induced epithelial-mesenchymal transition in peritoneal mesothelial cells and attenuates peritoneal fibrosis
As an electrophilic nitroalkene fatty acid, nitro-oleic acid (OA-NO2) exerts multiple biological effects that contribute to anti-inflammation, anti-oxidative stress and anti-apoptosis. However, little is known about the role of OA-NO2 in peritoneal fibrosis. Thus, in this study, we examined the effects of OA-NO2 on the high glucose-induced epithelial-mesenchymal transition (EMT) in human peritoneal mesothelial cells (HPMCs) and evaluated the morphological and immunohistochemical changes in a rat model of peritoneal dialysis (PD)-related peritoneal fibrosis. In an in vitro study, we found that HG reduced the expression level of E-cadherin and increased snail, N-cadherin and α-SMA expression levels in the HPMCs. The abovementioned changes were attenuated by pre-treatment with OA-NO2. Additionally, OA-NO2 also inhibited the HG-induced activation of the TGF-β1/Smads signalling pathway and the NF-κB signalling pathways. Meanwhile, OA-NO2 could inhibited the HG-induced phosphorylation of Erk and JNK. The results from the in vivo study showed that OA-NO2 notably relieved peritoneal fibrosis by decreasing the thickness of the peritoneum; it also inhibited the expression of TGF-β1, α-SMA, N-cadherin and vimentin and enhanced the expression of E-cadherin in the peritoneum. Collectively, these results suggest that OA-NO2 inhibits HG-induced EMT in HPMCs and attenuates peritoneal dialysis-related peritoneal fibrosis.
- 9 June 2015
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 240 (12) , 1717-1727
The liver X receptor agonist TO901317 protects mice against cisplatin-induced kidney injury
Liver X receptors are in the nuclear receptor superfamily and are contained in the regulation of lipid and cholesterol metabolism. Besides, liver X receptors are considered crucial regulators of the inflammatory response and innate immunity. The current study evaluates the in vivo effects that the synthetic liver X receptor agonist TO901317 protects against cisplatin-induced kidney injury in mice. Mice received cisplatin administration through a single intraperitoneal injection (20 mg/kg in saline). And then the mice were treated with the TO901317 by daily gavage (10 mg/kg/day) 12 h postcisplatin administration, and cisplatin nephrotoxicity was evaluated. At 72 h after cisplatin treatment, elevated plasma urea and creatinine levels ( P < 0.05) were evidenced which indicates the renal dysfunction of the vehicle-treated mice, consistent with tubular necrosis, protein cast, dilation of renal tubules, and desquamation of epithelial cells in renal tubules. In contrast, the severity of renal dysfunction and histological damage was reduced in TO901317 treated mice ( P < 0.05). In accordance, circulating tumor necrosis factor alpha levels, renal tumor necrosis factor alpha, p47phox, gp91phox, and protein expression levels and COX-2 mRNA, renal monocyte chemoattractant protein 1, VACAM-1 mRNA and intercellular adhesion molecule-1 contents, and renal prostaglandin E2 amounts, were higher in samples from cisplatin-treated mice in comparison with controls ( P < 0.05) but attenuated in the TO901317 treatment group ( P < 0.05). Taken together, treatment with the liver X receptor agonist TO901317 ameliorated the inflammatory response and oxidative stress in cisplatin-induced kidney injury in mice.
- 9 June 2015
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 240 (12) , 1717-1727
The liver X receptor agonist TO901317 protects mice against cisplatin-induced kidney injury
Liver X receptors are in the nuclear receptor superfamily and are contained in the regulation of lipid and cholesterol metabolism. Besides, liver X receptors are considered crucial regulators of the inflammatory response and innate immunity. The current study evaluates the in vivo effects that the synthetic liver X receptor agonist TO901317 protects against cisplatin-induced kidney injury in mice. Mice received cisplatin administration through a single intraperitoneal injection (20 mg/kg in saline). And then the mice were treated with the TO901317 by daily gavage (10 mg/kg/day) 12 h postcisplatin administration, and cisplatin nephrotoxicity was evaluated. At 72 h after cisplatin treatment, elevated plasma urea and creatinine levels ( P < 0.05) were evidenced which indicates the renal dysfunction of the vehicle-treated mice, consistent with tubular necrosis, protein cast, dilation of renal tubules, and desquamation of epithelial cells in renal tubules. In contrast, the severity of renal dysfunction and histological damage was reduced in TO901317 treated mice ( P < 0.05). In accordance, circulating tumor necrosis factor alpha levels, renal tumor necrosis factor alpha, p47phox, gp91phox, and protein expression levels and COX-2 mRNA, renal monocyte chemoattractant protein 1, VACAM-1 mRNA and intercellular adhesion molecule-1 contents, and renal prostaglandin E2 amounts, were higher in samples from cisplatin-treated mice in comparison with controls ( P < 0.05) but attenuated in the TO901317 treatment group ( P < 0.05). Taken together, treatment with the liver X receptor agonist TO901317 ameliorated the inflammatory response and oxidative stress in cisplatin-induced kidney injury in mice.